Literature DB >> 8918510

The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria.

C Andersson1, L Bjersing, F Lithner.   

Abstract

OBJECTIVE: To describe the epidemiology, pathogenesis and clinical features of hepatocellular carcinoma (HCC) in patients with acute intermittent porphyria (AIP).
DESIGN: A retrospective population-based mortality study.
SUBJECTS: All inhabitants who died between 1978-1990 (2122) including 33 with AIP, in two municipalities in northern Sweden with a high prevalence of AIP.
INTERVENTIONS: Death certificates and hospital records were examined. Histological re-examination of paraffin-embedded specimens from patients with HCC was performed and hepatitis B virus content analysed.
RESULTS: HCC was found in 27% of patients with AIP versus 0.2% of the deceased non-AIP subjects, P < 0.0001. HCC was more common in women (men:women 1:2) and in manifest AIP (manifest: latent 2:1). Liver cirrhosis was more common in AIP patients (12%), especially in women, compared with controls (0.5%), P < 0.0001.
CONCLUSIONS: AIP patients seem to have an increased risk of developing HCC. This tumour is more common in patients with manifest AIP and in women, a reversal of the usually reported gender ratio for HCC. No cause for developing HCC other than AIP was found. The pathogenesis may be explained by abnormalities in porphyrin metabolism and by intrinsic production of mutagenic substances, resulting in a condition of systemic overload of oxidative stress, enhancing mutation rate and liver cell injury. Liver cirrhosis appears to be more common in AIP patients and may be a preliminary stage to HCC. All AIP gene carriers aged > or = 55 should be screened for HCC.

Entities:  

Mesh:

Year:  1996        PMID: 8918510     DOI: 10.1046/j.1365-2796.1996.21847000.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  18 in total

1.  [A 25-year-old patient with colonic pseudo-obstruction, hyponatremia, hypertension, and diffuse pain].

Authors:  Philipp Lutz; Daniel Maring; Henriette J Tschampa; Tilman Sauerbruch
Journal:  Med Klin (Munich)       Date:  2010-04

2.  The incidence of inherited porphyrias in Europe.

Authors:  George Elder; Pauline Harper; Michael Badminton; Sverre Sandberg; Jean-Charles Deybach
Journal:  J Inherit Metab Dis       Date:  2012-11-01       Impact factor: 4.982

3.  Occurrence of Malignant Tumours in the Acute Hepatic Porphyrias.

Authors:  Estefanía Lang; Martin Schäfer; Holger Schwender; Norbert J Neumann; Jorge Frank
Journal:  JIMD Rep       Date:  2015-02-22

Review 4.  Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism.

Authors:  Ayelet Erez; Oleg A Shchelochkov; Sharon E Plon; Fernando Scaglia; Brendan Lee
Journal:  Am J Hum Genet       Date:  2011-04-08       Impact factor: 11.025

5.  High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria.

Authors:  Eliane Sardh; Staffan Wahlin; Mikael Björnstedt; Pauline Harper; Dan E H Andersson
Journal:  J Inherit Metab Dis       Date:  2013-01-23       Impact factor: 4.982

Review 6.  New advances in hepatocellular carcinoma.

Authors:  Sonia Pascual; Iván Herrera; Javier Irurzun
Journal:  World J Hepatol       Date:  2016-03-28

Review 7.  Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.

Authors:  Saranya Chidambaranathan-Reghupaty; Paul B Fisher; Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2020-11-28       Impact factor: 6.242

8.  Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis.

Authors:  Joanna K Dowman; Bridget K Gunson; Darius F Mirza; Simon R Bramhall; Mike N Badminton; Philip N Newsome
Journal:  Liver Transpl       Date:  2012-02       Impact factor: 5.799

9.  Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.

Authors:  Paolo Ventura; Herbert L Bonkovsky; Laurent Gouya; Paula Aguilera-Peiró; D Montgomery Bissell; Penelope E Stein; Manisha Balwani; D Karl E Anderson; Charles Parker; David J Kuter; Susana Monroy; Jeeyoung Oh; Bruce Ritchie; John J Ko; Zhaowei Hua; Marianne T Sweetser; Eliane Sardh
Journal:  Liver Int       Date:  2021-11-16       Impact factor: 8.754

10.  Increased porphyrins in primary liver cancer mainly reflect a parallel liver disease.

Authors:  Jerzy Kaczynski; Göran Hansson; Sven Wallerstedt
Journal:  Gastroenterol Res Pract       Date:  2009-10-18       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.